| Journal: | Memorias do Instituto Oswaldo Cruz |
| Database: | PERIÓDICA |
| System number: | 000459455 |
| ISSN: | 0074-0276 |
| Authors: | Nunes, Desiree dos Santos1 Higa, Luiza M2 Oliveira, Régis Linhares1 da Costa, Lendel Correia2 Bomfim, Larissa Maciel2 Gonçalves, Cássia Cristina Alves2 Mariani, Diana2 Hruby, Dennis E3 Voloch, Carolina Moreira2 Castiñeiras, Terezinha Marta Pereira Pinto4 Tanuri, Amilcar2 Damaso, Clarissa R1 |
| Institutions: | 1Universidade Federal do Rio de Janeiro, Instituto de Biofísica Carlos Chagas Filho, Rio de Janeiro. Brasil 2Universidade Federal do Rio de Janeiro, Instituto de Biologia, Rio de Janeiro. Brasil 3SIGA Technologies, Inc., Corvallis, Oregon. Estados Unidos de América 4Universidade Federal do Rio de Janeiro, Nucleo de Enfrentamento e Estudos de Doencas Infecciosas Emergentes e Reemergentes, Rio de Janeiro. Brasil |
| Year: | 2023 |
| Volumen: | 118 |
| Country: | Brasil |
| Language: | Inglés |
| Document type: | Artículo |
| Approach: | Experimental, aplicado |
| English abstract | In 2022, an outbreak of mpox that started in European countries spread worldwide through human-to-human transmission. Cases have been mostly mild, but severe clinical presentations have been reported. In these cases, tecovirimat has been the drug of choice to treat patients with aggravated disease. OBJECTIVES Here we investigated the tecovirimat susceptibility of 18 clinical isolates of monkeypox virus (MPXV) obtained from different regions of Brazil. METHODS Different concentrations of tecovirimat were added to cell monolayers infected with each MPXV isolate. After 72 hours, cells were fixed and stained for plaque visualization, counting, and measurement. The ortholog of F13L gene from each MPXV isolate was polymerase chain reaction (PCR)-amplified, sequenced, and the predicted protein sequences were analyzed. FINDINGS The eighteen MPXV isolates generated plaques of different sizes. Although all isolates were highly sensitive to the drug, two showed different response curves and IC50 values. However, the target protein of tecovirimat, F13 (VP37), was 100% conserved in all MPXV isolates and therefore does not explain the difference in sensitivity. MAIN CONCLUSIONS Our results support screening different MPXV isolates for tecovirimat susceptibility as an important tool to better use of the restricted number of tecovirimat doses available in low-income countries to treat patients with mpox |
| Disciplines: | Medicina |
| Keyword: | Virus, Farmacología, Viruela del mono, Poxvirus, Tecomirivat |
| Keyword: | Virus, Pharmacology, Monkey pox, Poxvirus, Tecomirivat |
| Full text: | Texto completo (Ver HTML) Texto completo (Ver PDF) |
